Cognition Therapeutics, Inc. Common Stock
$1.02
-$0.01 (-1.45%)
$1.01Day Range$1.07
Key Statistics
Market Cap
$98.42M
Shares Outstanding
95.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 8, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.04
Day High
$1.07
Day Low
$1.01
Volume
531.7K
VWAP
$1.05
Prev Close
$1.03
Transactions
--
Acc. Volume
--
About Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283614 employees2500 WESTCHESTER AVE, PURCHASE, NY, 10577412-481-2210IPO Oct 8, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001455365
- Composite FIGI
- BBG001J2P8S7
- Share Class FIGI
- BBG001V0GFB9
- Ticker Root
- CGTX
- SIC Code
- 2836
About Cognition Therapeutics, Inc. Common Stock (CGTX) Stock
Cognition Therapeutics, Inc. Common Stock (CGTX) closed the 2026-09-16 session at $1.02, down 1.45% versus the previous close (-0.01). The stock opened at $1.04 and traded between $1.01 and $1.07 during that session. Session trading volume was 532K shares. The volume-weighted average price (VWAP) is $1.05.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
Cognition Therapeutics, Inc. Common Stock has a market capitalization of $98.4 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CGTX is listed on the XNAS exchange. The company employs approximately 14 people. Cognition Therapeutics, Inc. Common Stock is headquartered in PURCHASE, NY. The recorded listing date is 2021-10-08.
On this page you can find market CGTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.